5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behçet's patients with or without ocular involvement

British Journal of Ophthalmology

Volumn 89, Issue 12, 2005, Pages 1634-1637

  Ozkul Y T ^a   Evereklioglu, Cem ^a,b   Borlu, M ^a   Taheri, S ^a   Calis, M ^a   Dundar M ^a   Ilhan, O ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA FRAGMENT; GENOMIC DNA; HOMOCYSTEINE; NUCLEOTIDE;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BEHCET DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENITAL ULCER; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; BEHCET SYNDROME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PANUVEITIS; POLYMORPHISM, GENETIC;

EID: 28444440613     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.076836     Document Type: Article

References (40)

1. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103:294-9.
2. Ueland PM, Hustad S, Refsum H, et al. Biological and clinical implications of the MTHFR 677C 3 T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
3. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000;84:154-7.
4. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297-350.
5. Üstün C. A famous Turkish dermatologist, Dr Hulusi Behçet. Eur J Dermatol 2002;12:409-70.
6. Borlu M, Uksal U, Ferahbas A, Evereklioglu C. Clinical features of Behçet's disease in children. Int J Dermatol 2005 (in press).
7. Inalöz HS, Evereklioglu C, Ünal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome. J Eur Acad Dermatol Venereol 1937;18:56-61.
8. Evereklioglu C, Çokkeser Y, Doganay S, et al. Audio-vestibular evaluation in patients with Behçet's syndrome. J Laryngol Otol 2001;115:704-8.
9. Evereklioglu C, Er H. Increased corneal thickness in active Behçet's disease. Eur J Ophthalmol 2002;12:24-9.
10. Idil A, Gürler A, Boyvat A, et al. The prevalence of Behçet's disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol 2002;9:325-31.
11. Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 2003;42:803-6.
12. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother 2004;5:317-28.
13. Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002;86:653-7.
14. Canataroglu A, Tanriverdi K, Inal T, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease. Rheumatol Int 2003;23:236-40.
15. Ateş A, Aydintug O, Ölmez U, et al. Serum homocysteine level is higher in Behçet's disease with vascular involvement. Rheumatol Int 2005;25:42-4.
16. Yeşilova Z, Pay S, Öktenli C, et al. Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy? Rheumatol Int 2005 (in press).
17. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
18. Blin N, Stafford DW. A general method for isolation of high molecular weigth DNA from Eukaryotes. Nucleic Acids Res 1976;3:2303-8.
19. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
20. Haznedaroglu IC, Özcebe O, Çelik I, et al. Haemostatic markers of procoagulant imbalance in Behçet's disease. Eur J Haematol 1996;57:107-8.
21. Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37-43.
22. Gül A, Aslantaş AB, Tekinay T, et al. Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology 1999;38:1298-9.
23. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol 1999;128:352-6.
24. Kiraz S, Ertenli I, Haznedaroglu IC, et al. Pathological haemostasis and "prothrombotic state" in Behçet's disease. Thromb Res 2002;105:125-33.
25. Batioglu F, Atmaca LS, Karabulut HG, et al. Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet's disease. Acta Ophthalmol Scand 2003;81:283-5.
26. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004;137:850-7.
27. Evereklioglu C, Er H, Türköz Y, Çekmen M. Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11:87-93.
28. Evereklioglu C, Inalöz HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. Br J Dermatol 2002;147:331-6.
29. Evereklioglu C, Türköz Y, Er H, et al. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol 2002;46:50-4.
30. Evereklioglu C, Çekmen M, Özkiriş A, et al. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behçet's disease. Mediators Inflamm 2003;12:255-6.
31. Erkiliç K, Evereklioglu C, Çekmen M, et al. Adenosine deaminase enzyme activity is increasea and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003;12:107-16.
32. Çekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol 2003;42:870-5.
33. Graham IM, Daly LE, Refsum HM, et al. Plasma Homocysteine as a risk factor for deep-vein trombosis. The European Concerted Action Project. J Am Med Assoc 1997;277:1775-7.
34. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocystenemia as a risk factor for deep-vein trombosis. N Engl J Med 21 1996;334:759-4.
35. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Sem Hematol 1997;34:171-7.
36. Seshadri N, Robinson K. Homocysteine, B vitamins and coronary artery disease. Med Clin North Am 2000;84:215-7.
37. Kang SS, Zhou J, Wong PW, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-21.
38. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A_C polymorphism in methylenetetrahydrofolate reductase: in vitro expression and association with homocysteine. Atherosclerosis 2001;156:409-15.
39. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13.
40. Food Nutrition Board, National Research Council. Folic acid: biochemistry and physiology in relation to human nutrition requirement. Washington, DC: National Academy of Sciences, 1977.